Formulation of Sustained-Release Ketorolac Tromethamine Pellets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation of Sustained-Release Ketorolac Tromethamine Pellets
The authors evaluated the effect of polymer composition on the drug-release profile and the effect of storage conditions on dissolution characteristics.


Pharmaceutical Technology
Volume 32, Issue 12, pp. 58-61

References

1. USP-DI (United States Pharmacopeial Convention Inc., 17th ed., Rockville, MD, 1997), p. 1788.

2. Physician's Desk Reference (Thomson PDR, 57th ed., Montvale, NJ, 2003), p. 2942.

3. M. Mori et al., "Prolongation of Antipyretic Action and Reduction of Gastric Ulcerogenicity in the Rat by Controlled-Release Granules of Bermoprofen, a New Nonsteroidal Anti-Inflammatory Drug," J. Pharm. Sci. 80, 876–880 (1991).

4. J. Rovensky and D. Micekova, "Six-Month Prospective Study to Monitor the Treatment of Rheumatic Diseases with Sustained-Release Flurbiprofen," Drug. Exp. Clin. Res. 26, 19–24 (2000).

5. T. Lee and J.R. Robinson, "Controlled-Release Drug-Delivery Systems," in Remington: The Science and Practice of Pharmacy (Lippincott Williams & Wilkins, 20th ed., Baltimore, MD, 2000), pp. 903–904.

6. L. Genc and N. Hegazy, "Sustained-Release Wax Matrix Formulations of Ketorolac Tromethamine with Compritol 888 ATO and HD 5 ATO," Acta Pharm. Turcia 42, 39–45 (2000).

7. D.M. Brahmankar, R.M. Karwa, and S.B. Jaiswal, "Cellulose Matrices for Controlled Release of Ketorolac Tromethamine," Indian Drugs 33, 120–123 (1996).

8. N. Vatsaraj, H. Zia, and T. Needham, "Formulation and Optimization of a Sustained-Release Tablet of Ketorolac Tromethamine," Drug Delivery 9, 153–159 (2002).

9. A.P. Rokhade et al., "Semi-Interpenetrating Polymer Network Microspheres of Gelatin and Sodium Carboxymethyl Cellulose for Controlled Release of Ketorolac Tromthamine," Carbohydrate Polymers 65, 243–252 (2006).

10. K. Ruckmani, M.S. Muneera, and R. Vijaya, "Eudragit Matrices for Sustained Release of Ketorolac Tromethamine and Kinetics of Release," Bollettino Chimico Farmaceutico 139, 205–208 (2000).

11. E.A. Hosny, A.A. Al-Helm, and E.M. Niazy, "In Vitro and In Vivo Evaluation of Commercial and Microcapsulated Sustained-Release Tablets Containing Diclofenac Sodium," Saudi Pharm. J. 6, 65–70 (1998).

12. M. Khan, J. Dib, and I.K. Reddy, "Statistical Optimization of Ketoprophen-Eudragit S-100 Coprecipitates to Obtain Controlled-Release Tablets," Drug Dev. Ind. Pharm. 22, 135–141 (1996).

13. C. Ho and G.C. Hwang, "Development of Extended-Release Solid Dispersions of Nonsteroidal Anti-Inflammatory Drugs with Aqueous Polymeric Dispersions: Optimization of Drug Release via a Curve-Fitting Technique," Pharm. Res. 9, 206–210 (1992).

14. J. Staniforth, "Powder Flow," in Pharmaceutics: The Science of Dosage Form Design, M.E. Aulton, Ed. (Churchill Livingstone, 2nd ed., Edinburgh, Scotland, 2002), pp. 205–207.

15. USP 26–NF 21 (United States Pharmacopeial Convention Inc., Rockville, MD, 2002), pp. 978–980.

16. R.K. Chang and A.J. Shukla, "Polymethacrylates," in Handbook of Pharmaceutical Excipients, R.C. Rowe, P.J. Shesky, and P.J. Weller, Eds. (Pharmaceutical Press, 4th ed., London, England, 2002), pp. 462–468.

17. L. Genc, E. Guler, and N. Hegazy, "Film-Coated Enteric Tablet Formulation of Ketorolac Tromethamine," Drug Dev. Ind. Pharm. 23, 1007–1011 (1997).

18. T. Higuchi, "Mechanism of Sustained Action Medication. Theoretical Analysis of Rate Release of Solid Drugs Dispersed in Solid Matrices," J. Pharm. Sci. 52, 1145–1149 (1963).

19. M. Donbrow, and S. Benita, "Release Kinetics of Sparingly Soluble Drugs from Ethyl Cellulose–Walled Microcapsules: Salicylamide Microcapsules," J. Pharm. Pharmacol. 34, 547–551 (1982).

20. Z. Qiu et al., "Effect of Milling and Compression on the Solid-State Maillard Reaction," J. Pharm. Sci. 94, 2568–2580 (2005).

21. R.C. George et al., "Investigation into the Yellowing on Aging of Sabril Tablet Cores," Drug Dev. Ind. Pharm. 20, 3023–3032 (1994).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here